chevron_leftBack
As of 24 April 2025, Cyfuse Biomedical K.K. has a market cap of $54.85M USD, ranking #24169 globally and #2658 in Japan. It ranks #2447 in the Healthcare sector, and #538 in the Drug Manufacturers - Specialty & Generic industry.
Key Stats
Market Cap
$54.85MUSD
7.82B JPY
Enterprise Value
$39.41MUSD
5.62B JPY
Revenue (TTM)
$378.97KUSD
54.0M JPY
EBITDA (TTM)
-$6.02MUSD
-858.0M JPY
Net Income (TTM)
-$6.12MUSD
-872.0M JPY
Company Profile
Country (HQ)
Sector
Healthcare
CEO
Shizuka Akieda
open_in_new
Employees
21
Founded
2010
Website
cyfusebio.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -0.6% | 0.6% | 2.6% | 116% | 79% | 41% |
Upcoming Earnings
Earnings Date
Thu, May 15
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
4892
株式会社サイフューズ
ISIN: JP3311800001
Shares Out.:
Shares Outstanding:
8.205M1
Shares Float:
5.281M2
|
984 JPY |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Cyfuse Biomedical K.K.
Cyfuse Biomedical K.K. engages in the development, manufacture, and sale of regenerative medicine products in Japan. It develops cellular products in the field of regenerative therapy; and undertakes contract for cellular products for research and development. The company also offers Bio 3D Printer for use in the regeneration of various tissues and organs, such as cartilage and bones, blood vessels, and nerves; regenova, a bio 3D printer for 3D stacking of cells; and S-PIKE that develops 3D-structures from cells. Cyfuse Biomedical K.K. was incorporated in 2010 and is based in Tokyo, Japan.
